Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study

Abstract

In the majority of patients with stable low DAS28 and stable treatment, infliximab can be down-titrated or discontinued, which results in a considerable reduction in costs without influencing QoL.

Relapses of sarcoidosis: what are they and can we predict who will get them?

“…In one study in which the drug was withdrawn after 1 year or less, 90% of patients had recurrence of their symptomatic disease [28]. This high rate of relapse is similar to what has been recorded in rheumatoid arthritis patients [29].…”

Treatment strategies in rheumatoid arthritis

“…In this study, 39% of patients were biologic-free (most of them were still on MTX) 3 years and 34% of them 4 years after treatment initiation [29]. Van der Maas et al [36] assessed IFX tapering and discontinuation. When 25% or 50% dose reduction was performed, 75% of the patients did not flare after one year.…”

“…Van der Maas i wsp. [36] oceniali stopniowe zmniejszanie dawki i odstawienie IFX. Gdy dawkę zmniejszono o 25% lub 50%, u 75% pacjentów nie doszło do zaostrzenia choroby po roku, natomiast redukcja dawki o 75% powodowała zaostrzenie choroby wymagają-ce ponownego zwiększenia dawki u 50% pacjentów.…”

Strategy for Dose Reduction and Discontinuation of Biological Agents in Rheumatoid Arthritis Remission

“…Van der Maas и соавт. [21] одними из первых провели наблюдательное исследование прогрессивного снижения дозы ИНФ у 51 пациента с РА при DAS28 <3,2 более 6 мес. Длительность РА у них соста-вляла ≥12 лет, и они получали ГИБП в среднем в течение 5,6 года.…”